Overview
Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate and titration-dependent. Serious adverse events were uncommon but more frequent than with placebo in STEP-1.
Released: Last reviewed:
Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate and titration-dependent. Serious adverse events were uncommon but more frequent than with placebo in STEP-1.
Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Mostly mild-moderate and titration-dependent. Serious adverse events were uncommon but more frequent than with placebo in STEP-1.